[{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Phase 2 Clinical Trial Has Received Ethics Approval for World First Take-Home LSD-Microdosing Trials in Cancer Patients Experiencing Emotional Distress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Breakthrough Discovery in Microdosing Clinical Trial Reveals Significant Positive Effects on Quality Of Sleep","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder Begins Pre-Screening Participants","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by MindBio Therapeutics
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
MB22001 (Lysergic acid diethylamide) is titratable form of LSD for take-home microdosing. It is being evaluated in phase 2 clinical trials for the treatment of Major Depressive Disorder.
MB22001 (lysergic acid diethylamide) is a 5-HT2 receptor inhibitor, small molecule drug candidate. It is being evaluated for the treatment of depression in cancer patients.
MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe and effective take home microdosing in patients suffering from Major Depressive Disorder.
MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe and effective take home microdosing in patients suffering from Major Depressive Disorder.
Lysergic Acid Diethylamide is a potent psychoactive substance which binds to the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. It is being investigated for major depressive disorder.
Lysergic Acid Diethylamide is a potent psychoactive substance which binds to the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. It is being investigated as Major Depressive Disorder.
Lysergic Acid Diethylamide is a potent psychoactive substance which binds to the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. It is being investigated as Improves Sleep.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
